Oxidative stress in patients on regular hemodialysis and peritoneal dialysis

1. Teplan V et al. Praktická nefrologie. Praha: Grada 2006.

2. Del Vecchio L, Locatelli F, Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis – clinical effects, potential treatment, and prevention. Semin Dial 2011; 24: 56–64.

3. Vostálová J, Galandáková A, Štrebl P et al. Oxidační stres u pacientů s onemocnění ledvin. Vnitř Lék 2012; 58: 202–207.

4. Kadkhodaee M, Hemmati M, Zahmatkesh M et al. Assessment of plasma antioxidant status in hemodialysis patients. Ther Apher Dial 2008; 12: 147–151.

5. Coaccioli S, Standoli ML, Biondi R et al. Assessment of the oxidative stress markers in patients with chronic renal insufficiency undergoing dialysis treatment. Clin Ter 2010; 161: 441–444.

6. Caussé E, Ribes D, Longlune N et al. Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions. Clin Nephrol 2010; 73: 51–57.

7. Witasp A, Carrero JJ, Heimbürger O et al. Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients. J Intern Med 2011; 269: 410–419.

8. Mekki K, Taleb W, Bouzidi N et al. Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis 2010; 9: 93.

9. Montazerifar F, Hashemi M, Karajibani M et al. Hemodialysis alters lipid profiles, total anti­oxidant capacity, and vitamins A, E, and C concentrations in humans. J Med Food 2010; 13: 1490–1493.

10. Michelis R, Kristal B, Snitkovsky T et al. Oxidative modifications impair albumin quantification. Biochem Biophys Res Commun 2010; 401: 137–142.

11. Libetta C, Sepe V, Esposito P et al. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem 2011; 44: 1189–1198.

12. Mitrogianni Z, Barbouti A, Galaris D et al. Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis pa­tients. Nephron Clin Pract 2009; 113: 234–240.

13. Choi JY, Yoon YJ, Choi HJ et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol Dial Transplant 2010; 26: 1304–1313.

14. Filiopoulos V, Hadjiyannakos D, Takouli L et al. Inflammation and oxidative stress in end--stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs 2009; 32: 872–882.

15. Castoldi G, Antolini L, Bombardi C et al. Oxidative stress biomarkers and chromogranin A in uremic patients: effects of dialytic treatment. Clin Biochem 2010; 43: 1387–1392.

16. Fassett RG, Driver R, Healy H et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients – an observational study. BMC Nephrol 2009; 10: 8–14.

17. Opatrná S. Peritoneální dialyzační roztoky druhé generace: preklinické studie a klinické zkušenosti. Plzeň: Euroverlag 2009.

18. Rabbani N, Thornalley PJ. Quantitation of markers of protein damage by glycation, oxidation, and nitration in peritoneal dialysis. Perit Dial Int 2009; 29 (Suppl 2): S51–S56.

19. Lai KN, Leung JC. Inflammation in peritoneal dialysis. Nephron Clin Pract 2010; 116: 11–18.

20. Kocak H, Gumuslu S, Sahin E et al. Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients. Nephrology (Carlton) 2009; 14: 273–280.

21. Tarng DC, Wen Chen T, Huang TP et al. Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients. J Am Soc Nephrol 2002; 13: 1321–1330.

22. Ignace S, Fouque D, Arkouche W et al. Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24: 1685–1689.

23. Furuya R, Kumagai H, Odamaki M et al. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009; 112: c255–c261.

24. Singer R, Rhodes HC, Chin G et al. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton) 2008; 13: 17–22.

25. Guo CH, Wang CL, Chen PC et al. Linkage of some trace elements, peripheral blood lymphocytes, inflammation, and oxidative stress in patients undergoing either hemodialysis or peritoneal dialysis. Perit Dial Int 2011; 31: 583–591.

26. Demirci S, Sekeroğlu MR, Noyan T et al. The importance of oxidative stress in patients with chronic renal failure whose hypertension is treated with peritoneal dialysis. Cell Biochem Funct 2011; 29: 249–254.

27. Włodek P, Marcykiewicz B, Iciek M et al. Thiol levels, protein carbonylation and anaerobic sulfur metabolism in erythrocytes of peritoneal dialysis and predialysis patients. Nephrology (Carlton) 2010; 15: 755–761.

28. Chung AW, Yang HH, Kim JM et al. Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: an exploratory study. Nephrol Dial Transplant 2010; 25: 4031–4041.

29. Sundl I, Roob JM, Meinitzer A et al. Antioxidant status of patients on peritoneal dialysis: associations with inflammation and glycoxidative stress. Perit Dial Int 2009; 29: 89–101.

30. Eiselt J, Racek J, Opatrný jr. K. Volné radikály a mimotělní náhrada funkce ledvin. Vnitř Lék 1999; 45: 319–324.

31. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272–1280.

32. Lim PS, Wei YH, Yu YL et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680–2687.

33. Hörl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007; 22: 480–489.

34. Tarng DC, Huang TP, Wei YH et al. 8-hydro­xy-2‘-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934–944.

35. Stuard S, Bonomini M, Settefrati N et al. Platelet-neutrophil interactions during hemodialysis: a proposed biocompatibility approach. Int J Artif Organs 1998; 21: 75–82.

36. Itoh S, Susuki C, Tsuji T. Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. J Biomed Mater Res A 2006; 77: 294–303.

37. Riegel W, Leverenz K, Schollmeyer P et al. Plasma levels of main granulocyte components during hemodialysis: effects of immunosuppression. Nephron 1987; 46: 161–166.

38. Ono K, Ueki K, Inose K et al. Plasma levels of myeloperoxidase and elastase are differentially regulated by hemodialysis membranes and anticoagulants. Res Commun Mol Pathol Pharmacol 2000; 108: 341–349.

39. Wu CC, Chen JS, Wu WM et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20: 1134–1139.

40. Krieter DH, Morgenroth A, Barasinski A et al. Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins. Nephrol Dial Transplant 2007; 22: 491–499.

41. Morena M, Delbosc S, Dupuy AM et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37–46.

42. Lubrano R, Taccone-Gallucci M, Piazza A et al. Vitamin E supplementation and oxidative status of peripheral blood mononuclear cells and lymphocyte subsets in hemodialysis patients. Nutrition 1992; 8: 94–97.

43. Buoncristiani U, Galli F, Rovidati S et al. Oxidative damage during hemodialysis using a vitamin-E-modified dialysis membrane: a preliminary characterization. Nephron 1997; 77: 57–61.

44. Galli F, Rovidati S, Chiarantini L et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998; 54: 580–589.

45. Cruz DN, de Cal M, Ronco C. Oxidative stress and anemia in chronic hemodialysis: the promise of bioreactive membranes. Contrib Nephrol 2008; 161: 89–98.

46. Tarng DC, Huang TP, Liu TY et al. Effect of vitamin E-bonded membrane on the 8-hydroxy 2‘-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000; 58: 790–799.

47. Cruz DN, De Cal M, Garzotto F et al. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. Int J Artif Organs 2008; 31: 545–552.

48. Eiselt J, Racek J, Trefil L et al. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001; 25: 430–436.

49. Yang CC, Hsu SP, Wu MS et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69: 706–714.

50. Mune M, Yukawa S, Kishino M et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 1999; 71: S126–S129.

51. Morena M, Jaussent I, Chalabi L et al. Biocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int 2010; 14: 403–410.

52. Alhamdani MS, Al-Najjar AF, Al-Kassir AH. The effect of hemodialysis and dialyzer biocompatibility on erythrocyte glutathione-defense system in chronic hemodialysis patients. Int J Artif Organs 2005; 28: 576–582.

53. Kayabasi H, Sit D, Atay AE et al. Parameters of oxidative stress and echocardiographic indexes in patients on dialysis therapy. Ren Fail 2010; 32: 328–334.

54. Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in pa­tients with end-stage renal disease. Clin Biochem 2005; 38: 700–705.

55. Akiyama S, Inagaki M, Tsuji M et al. mRNA study on Cu/Zn superoxide dismutase induction by hemodialysis treatment. Nephron Clin Pract 2005; 99: c107–c114.

56. Olszewska M. The effect of hemodialysis on some parameters of the antioxidant system in the blood of patients with chronic renal failure. Ann Acad Med Stetin 2004; 50: 41–52.

57. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484–494.

58. Štípek S et al. Antioxidanty a volné radikály ve zdraví a v nemoci. Praha: Grada 2000.

59. Ward RA, McLeish KR. Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003; 27: 230–236.

60. Hurst JK, Barrette WC jr. Leukocytic oxygen activation and microbicidal oxidative toxins. Crit Rev Biochem Mol Biol 1989; 24: 271–328.

61. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636–643.

62. Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999; 133: 321–325.

63. Himmelfarb J, Mc Menamin ME, Loseto G et al. Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163–1169.

64. Bargnoux AS, Morena M, Badiou S et al. Groupe de travail de la SFBC: Biologie des fonctions renales et de l’insuffisance renale. Carbonyl stress and oxidatively modified proteins in chronic renal failure. Ann Biol Clin (Paris) 2009; 67: 153–158.

65. Deicher R, Hörl WH. Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press Res 2003; 26: 100–106.

66. Keven K, Kutlay S, Nergizoglu G et al. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233–1239.

67. Weissinger EM, Nguyen-Khoa T, Fumeron C et al. Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. Proteomics 2006; 6: 993–1000.

68. Yang CC, Hsu SP, Wu MS et al. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006; 69: 706–714.

69. Attallah N, Osman-Malik Y, Frinak S et al. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47: 644–654.

70. Fumeron C, Nguyen-Khoa T, Saltiel C et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 1874–1879.

71. Chan D, Irish A, Croft KD et al. Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 234–235.

72. Chen WT, Lin YF, Yu FC et al. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Am J Kidney Dis 2003; 42: 158–166.

73. Deicher R, Ziai F, Bieglmayer C et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 1811–1818.

74. De Vriese AS, Borrey D, Mahieu E et al. Oral vitamin C administration increases lipid peroxidation in hemodialysis patients. Nephron Clin Pract 2008; 108: c28–c34.

75. Deved V, Poyah P, James MT et al. Alberta Kidney Disease Network. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1089–1097.

76. Washio K, Inagaki M, Tsuji M et al. Oral vitamin C supplementation in hemodialysis pa­tients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker. Nephron Clin Pract 2008; 109: c49–c54.

77. Hodkova M, Dusilova Sulkova S, Kalousova M et al. Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail 2006; 28: 395–399.

78. Akiyama S, Inagaki M, Tsuji M et al. Comparison of effect of vitamin E-coated dialyzer and oral vitamin E on hemodialysis-induced Cu/Zn-superoxide dismutase. Am J Nephrol 2005; 25: 500–506.

79. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213–1218.

80. Kamgar M, Zaldivar F, Vaziri ND et al. Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. J Natl Med Assoc 2009; 101: 336–344.

81. Zachara BA, Gromadzińska J, Wasowicz W et al. Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review. Acta Biochim Pol 2006; 53: 663–677.

82. Taccone-Gallucci M, Noce A, Bertucci P et al. Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients. J Trace Elem Med Biol 2010; 24: 27–30.

83. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382–393.

84. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070–2076.

85. Sun Y, Stidley CA, Harford AM et al. Increased cardiovascular and infectious deaths in hemodialysis (HD) patients treated with high dose intravenous iron therapy. J Am Soc Nephrol 2002; 13: 434A.

86. Bayés B, Pastor MC, Bonal J et al. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis – role of seniority and intravenous ferrotherapy: analysis at 4 Years of follow-up. Nephrol Dial Transplant 2006; 21: 984–990.

87. Swarnalatha G, Ram R, Neela P et al. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl 2010; 21: 852–858.

88. Hodkova M, Dusilova Sulkova S, Skalicka A et al. Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis pa­tients. Ren Fail 2005; 27: 135–141.

89. Sommerburg O, Grune T, Hampl H et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998; 13: 2583–2587.

90. Ludat K, Sommerburg O, Grune T et al. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000; 53: S30–S35.

91. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb Res 2007; 120: 797–803.

92. Monostori P, Hracskó Z, Karg E et al. Erythropoiesis-stimulating agent withdrawal and oxidative stress in hemodialysis. Clin Nephrol 2009; 71: 521–526.

93. Swant J, Nair S, Redkar N. Oxidative stress and serum paraoxonase activity in patients on maitenance hemodialysis. Internet J Nephrol 2010; 6.

94. Gugliucci A, Kinugasa E, Kotani K et al. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 2011, 49: 61–67.

95. Granata S, Zaza G, Simone S et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009; 10: 388–400.